Vascular cognitive impairment (VCI) describes a wide spectrum of cognitive deficits related
to cerebrovascular diseases. Although the loss of blood flow to cortical regions critically …

Identifying biomarkers of Alzheimer's disease (AD) will accelerate the understanding of its
pathophysiology, facilitate screening and risk stratification, and aid in developing new …

Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in
2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild …

The blood-brain barrier (BBB) is a complex and dynamic physiological interface between
brain parenchyma and cerebral vasculature. It is composed of closely interacting cells and …

Background There has been ongoing research impetus to uncover novel blood-based
diagnostic and prognostic biomarkers for Alzheimer's disease (AD), vascular dementia …

Background Dementia is a debilitating neurological condition that affects millions of patients
and families worldwide and remains a significant public health concern. Understanding the …

Introduction Hippocampal atrophy is an established Alzheimer's Disease (AD) biomarker.
Volume loss in specific subregions as measurable with ultra-high field magnetic resonance …

White matter hyperintensities (WMH) and β-amyloid (Aβ) accumulation have both been
linked to neurodegeneration in Alzheimer's disease (AD). However, the independent effects …

Background Dementia is a progressive neurocognitive disease with a substantial social
burden. No apparent breakthroughs in treatment options have emerged so far; thus, disease …

Background: The relation between vascular risk factors (VRFs) and Alzheimer's disease
(AD) is important due to possible pathophysiological association. Objective: To assess the …